Vancouver – Rates of hepatitis C reinfection among people who inject drugs are significantly reduced in those receiving opioid substitution therapy and mental health counselling.
That was one of the findings of a new BC Centre for Disease Control (BCCDC) study published in The Lancet Gastroenterology & Hepatology
. The study, Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study
is available online
The BCCDC hepatitis team, using its landmark dataset - BC Hepatitis Testers Cohort (BC-HTC) conducted the study to assess the role of various interventions in preventing hepatitis C (HCV) reinfection among those injecting drugs.
The study found that receiving opioid substitution therapy and being engaged with mental health counselling services were independently associated with a significantly lower likelihood of HCV reinfection.
Read the full news release
on this research and the article, Islam N, et al. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study
, The Lancet Gastroenterology & Hepatology,
December 22, 2016.
BC Centre for Disease Control
604-707-2412 or PHSA media line 778-867-7472